InvestorsHub Logo
Followers 5
Posts 856
Boards Moderated 0
Alias Born 09/28/2012

Re: None

Wednesday, 01/09/2019 3:14:06 PM

Wednesday, January 09, 2019 3:14:06 PM

Post# of 8494
As expected, royalties will be flat in 2019 but should increase meaningfully in 2020 and beyond to hopefully reach $1B in 2027.

Interesting that an Enhanze partner is supposed to enter a phase 3 study for an undisclosed target. I did not know one could keep it undisclosed that long.

"In the second half of 2019, ENHANZE partner Janssen Biotech, Inc. anticipates filing for approval of the SC formulation of its multiple myeloma drug daratumumab (Darzalex®). Also in the second half, Halozyme expects a phase 3 study will be initiated by a partner for an undisclosed target."

https://ih.advfn.com/stock-market/NASDAQ/halozyme-therapeutics-inc-HALO/stock-news/79023226/halozyme-provides-2019-pipeline-update-and-financi
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent HALO News